395 related articles for article (PubMed ID: 35616826)
1. Current and Future Therapeutic Options in Pain Management: Multi-mechanistic Opioids Involving Both MOR and NOP Receptor Activation.
Coluzzi F; Rullo L; Scerpa MS; Losapio LM; Rocco M; Billeci D; Candeletti S; Romualdi P
CNS Drugs; 2022 Jun; 36(6):617-632. PubMed ID: 35616826
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic potentials of NOP and MOP receptor coactivation for the treatment of pain and opioid abuse.
Kiguchi N; Ding H; Ko MC
J Neurosci Res; 2022 Jan; 100(1):191-202. PubMed ID: 32255240
[TBL] [Abstract][Full Text] [Related]
3. Effects of spinally administered bifunctional nociceptin/orphanin FQ peptide receptor/μ-opioid receptor ligands in mouse models of neuropathic and inflammatory pain.
Sukhtankar DD; Zaveri NT; Husbands SM; Ko MC
J Pharmacol Exp Ther; 2013 Jul; 346(1):11-22. PubMed ID: 23652222
[TBL] [Abstract][Full Text] [Related]
4. Nociceptin/Orphanin FQ Peptide Receptor-Related Ligands as Novel Analgesics.
Kiguchi N; Ding H; Kishioka S; Ko MC
Curr Top Med Chem; 2020; 20(31):2878-2888. PubMed ID: 32384033
[TBL] [Abstract][Full Text] [Related]
5. A novel orvinol analog, BU08028, as a safe opioid analgesic without abuse liability in primates.
Ding H; Czoty PW; Kiguchi N; Cami-Kobeci G; Sukhtankar DD; Nader MA; Husbands SM; Ko MC
Proc Natl Acad Sci U S A; 2016 Sep; 113(37):E5511-8. PubMed ID: 27573832
[TBL] [Abstract][Full Text] [Related]
6. Nociceptin Receptor-Related Agonists as Safe and Non-addictive Analgesics.
Ding H; Kiguchi N; Dobbins M; Romero-Sandoval EA; Kishioka S; Ko MC
Drugs; 2023 Jun; 83(9):771-793. PubMed ID: 37209211
[TBL] [Abstract][Full Text] [Related]
7. BU10038 as a safe opioid analgesic with fewer side-effects after systemic and intrathecal administration in primates.
Kiguchi N; Ding H; Cami-Kobeci G; Sukhtankar DD; Czoty PW; DeLoid HB; Hsu FC; Toll L; Husbands SM; Ko MC
Br J Anaesth; 2019 Jun; 122(6):e146-e156. PubMed ID: 30916003
[TBL] [Abstract][Full Text] [Related]
8. [Therapeutic potentials of safe opioid analgesics targeting nociceptin/orphanin FQ peptide receptor].
Kiguchi N; Kishioka S; Ko MC
Nihon Yakurigaku Zasshi; 2021; 156(3):139-144. PubMed ID: 33952840
[TBL] [Abstract][Full Text] [Related]
9. Replacement of current opioid drugs focusing on MOR-related strategies.
Busserolles J; Lolignier S; Kerckhove N; Bertin C; Authier N; Eschalier A
Pharmacol Ther; 2020 Jun; 210():107519. PubMed ID: 32165137
[TBL] [Abstract][Full Text] [Related]
10. Antinociceptive Efficacy of the µ-Opioid/Nociceptin Peptide-Based Hybrid KGNOP1 in Inflammatory Pain without Rewarding Effects in Mice: An Experimental Assessment and Molecular Docking.
Dumitrascuta M; Bermudez M; Trovato O; De Neve J; Ballet S; Wolber G; Spetea M
Molecules; 2021 May; 26(11):. PubMed ID: 34071603
[TBL] [Abstract][Full Text] [Related]
11. Cebranopadol : a first-in-class potent analgesic agent with agonistic activity at nociceptin/orphanin FQ and opioid receptors.
Sałat K; Jakubowska A; Kulig K
Expert Opin Investig Drugs; 2015 Jun; 24(6):837-44. PubMed ID: 25865744
[TBL] [Abstract][Full Text] [Related]
12. Nociceptin/orphanin FQ receptor ligands and translational challenges: focus on cebranopadol as an innovative analgesic.
Calo G; Lambert DG
Br J Anaesth; 2018 Nov; 121(5):1105-1114. PubMed ID: 30336855
[TBL] [Abstract][Full Text] [Related]
13. Cebranopadol: a novel potent analgesic nociceptin/orphanin FQ peptide and opioid receptor agonist.
Linz K; Christoph T; Tzschentke TM; Koch T; Schiene K; Gautrois M; Schröder W; Kögel BY; Beier H; Englberger W; Schunk S; De Vry J; Jahnel U; Frosch S
J Pharmacol Exp Ther; 2014 Jun; 349(3):535-48. PubMed ID: 24713140
[TBL] [Abstract][Full Text] [Related]
14. The first universal opioid ligand, (2S)-2-[(5R,6R,7R,14S)-N-cyclopropylmethyl-4,5-epoxy-6,14-ethano-3-hydroxy-6-methoxymorphinan-7-yl]-3,3-dimethylpentan-2-ol (BU08028): characterization of the in vitro profile and in vivo behavioral effects in mouse models of acute pain and cocaine-induced reward.
Khroyan TV; Polgar WE; Cami-Kobeci G; Husbands SM; Zaveri NT; Toll L
J Pharmacol Exp Ther; 2011 Mar; 336(3):952-61. PubMed ID: 21177476
[TBL] [Abstract][Full Text] [Related]
15. Roles of μ-opioid receptors and nociceptin/orphanin FQ peptide receptors in buprenorphine-induced physiological responses in primates.
Cremeans CM; Gruley E; Kyle DJ; Ko MC
J Pharmacol Exp Ther; 2012 Oct; 343(1):72-81. PubMed ID: 22743574
[TBL] [Abstract][Full Text] [Related]
16. Designing safer analgesics: a focus on μ-opioid receptor pathways.
Pergolizzi JV; LeQuang JA; Taylor R; Ossipov MH; Colucci D; Raffa RB
Expert Opin Drug Discov; 2018 Oct; 13(10):965-972. PubMed ID: 30175624
[TBL] [Abstract][Full Text] [Related]
17. A bifunctional nociceptin and mu opioid receptor agonist is analgesic without opioid side effects in nonhuman primates.
Ding H; Kiguchi N; Yasuda D; Daga PR; Polgar WE; Lu JJ; Czoty PW; Kishioka S; Zaveri NT; Ko MC
Sci Transl Med; 2018 Aug; 10(456):. PubMed ID: 30158150
[TBL] [Abstract][Full Text] [Related]
18. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
19. Biased Opioid Ligands.
Faouzi A; Varga BR; Majumdar S
Molecules; 2020 Sep; 25(18):. PubMed ID: 32948048
[TBL] [Abstract][Full Text] [Related]
20. OREX-1038: a potential new treatment for pain with low abuse liability and limited adverse effects.
Gerak LR; Maguire DR; Cami-Kobeci G; Olson KM; Traynor JR; Husbands SM; France CP; Acevedo L; Belli B; Flynn P
Behav Pharmacol; 2022 Sep; 33(6):377-394. PubMed ID: 35947066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]